BLACK PEARL EXTENDS TENDER OFFER FOR ALL OUTSTANDING SHARES OF SELECTIS HEALTH, INC.

Black Pearl extended its tender offer for all outstanding Selectis Health (OTCQB: GBCS) shares, increasing the expiration window from Aug. 27, 2026 (5:00 p.m. ET) to Aug. 31, 2026 (5:00 p.m. ET), with price unchanged at $5.75/share in cash. As of Aug. 27, 2026, 2,786,482 shares had been validly tendered and not withdrawn. All other tender terms remain unchanged, suggesting a modest but focused impact on Selectis given the transaction timeline extension.

Analysis

This is less a fundamental update than a signal that the closing clock is slipping, which matters most in tiny-cap cash deals where every extra day burns annualized IRR and increases the odds of a papering, financing, or consent issue. The market should treat the extension as a modest negative for certainty, even if the ultimate outcome is still probably completion; in these situations, one more extension often matters far more than the current one because it tells you whether the parties are merely clearing mechanics or confronting a real condition.

The immediate winner is the arbitrage holder that can finance and borrow cheaply; the loser is anyone paying up for certainty too early. If the stock is already trading close to the offer, upside is capped while downside reopens quickly on any second extension, so the risk/reward is asymmetric against momentum longs. A failed deal would not just hurt the stock; it would likely re-rate the name back toward stressed small-cap healthcare valuation, where liquidity disappears and bid/ask gaps dominate price discovery.

The key contrarian read is that the market may be underpricing extension risk because tender counts create a false sense of inevitability. What matters is not shares tendered, but whether all remaining conditions can be satisfied without a financing or regulatory surprise; absent that, the tender count is mostly noise. For broader healthcare, this is not a sector read, but repeated hiccups in small private-to-public takeouts can widen required premiums across OTC healthcare names and make minority holders demand a higher control premium.

Catalyst timing is very short: days for the next deadline, 1-3 months for any further extension, and 6-18 months only if the transaction collapses and the company is forced back into standalone execution. The main falsifier for a bearish process view is immediate acceptance by the buyer or a clean final closing with no further extension; the main risk to a bearish stance is being squeezed if the tender is effectively locked and borrow is tight.

Key Decisions for Investors

• If already long GBCS in merger-arb, keep the position only through 8/31 if the spread still offers acceptable annualized carry; cut size immediately on any second extension because that is when probability of a real process issue steps up.
• Do not initiate a fresh long GBCS unless you can buy at a meaningful discount to $5.75 that compensates for delay risk; the trade is now a short-duration spread, not a directional bet.
• If borrow is available and the stock trades near the offer with another extension, consider a small short against the cash tender, but only after confirming there is no additional support from the buyer side; squeeze risk is high in illiquid OTC names.
• Set an alert for any filing or announcement that clarifies the remaining conditions to closing; a clean financing/regulatory confirmation is the only event that restores the original arb thesis.